All Stories

  1. T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy

    Article • Viruses, April 2024, MDPI AG

    Dr Mark A Brockman

  2. Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study

    Article • Vaccines, April 2024, MDPI AG

    Dr Mark A Brockman

  3. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy

    Article • mBio, November 2021, ASM Journals

    Dr Mark A Brockman

  4. Reduced magnitude and durability of humoral immune responses by COVID-19 mRNA vaccines among older adults

    Article • September 2021, Cold Spring Harbor Laboratory Press

    Dr Mark A Brockman

  5. HIV proviral burden, genetic diversity, and dynamics in viremic controllers who subsequently initiated suppressive antiretroviral therapy

    Article • March 2021, Cold Spring Harbor Laboratory Press

    Dr Mark A Brockman

  6. Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5

    Article • PLoS Pathogens, September 2020, PLOS

    Dr Mark A Brockman

  7. Consequences of HLA‐associated mutations in HIV‐1 subtype C Nef on HLA‐I downregulation ability

    Article • Journal of Medical Virology, February 2020, Wiley

    Dr Mark A Brockman

  8. Longitudinal within-host evolution of HIV Nef-mediated CD4, HLA and SERINC5 downregulation activity: a case study

    Article • Retrovirology, January 2020, Springer Science + Business Media

    Dr Mark A Brockman

  9. Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4+ T Cell Subsets during Long-Term Combination Antiretroviral Therapy

    Article • Journal of Virology, November 2019, ASM Journals

    Dr Mark A Brockman

  10. Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity

    Article • Cell Reports, November 2019, Elsevier

    Dr Mark A Brockman

  11. Measuring sexual relationship power equity among young women and young men South Africa: Implications for gender-transformative programming

    Article • PLoS ONE, September 2019, PLOS

    Dr Mark A Brockman

  12. Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection

    Article • Science Translational Medicine, May 2019, American Association for the Advancement of Science

    Dr Mark A Brockman

  13. Nef-mediated inhibition of NFAT following TCR stimulation differs between HIV-1 subtypes

    Article • Virology, May 2019, Elsevier

    Dr Mark A Brockman

  14. Modulation of TCR-dependent NFAT signaling is impaired in HIV-1 Nef isolates from elite controllers

    Article • Virology, April 2019, Elsevier

    Dr Mark A Brockman

  15. HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals

    Article • Journal of Virology, January 2019, ASM Journals

    Dr Mark A Brockman

  16. Expression of human inducible nitric oxide synthase in response to cytokines is regulated by hypoxia-inducible factor-1

    Article • Free Radical Biology and Medicine, January 2019, Elsevier

    Dr Mark A Brockman

  17. Implications of HIV-1 Nef for “Shock and Kill” Strategies to Eliminate Latent Viral Reservoirs

    Article • Viruses, November 2018, MDPI AG

    Dr Mark A Brockman

  18. Dual HLA B*42 and B*81-reactive T cell receptors recognize more diverse HIV-1 Gag escape variants

    Article • Nature Communications, November 2018, Springer Science + Business Media

    Dr Mark A Brockman

  19. Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity

    Article • Journal of Virology, October 2018, ASM Journals

    Dr Mark A Brockman

  20. A high burden of asymptomatic genital tract infections undermines the syndromic management approach among adolescents and young adults in South Africa: implications for HIV prevention efforts

    Article • BMC Infectious Diseases, October 2018, Springer Science + Business Media

    Dr Mark A Brockman

  21. Phylogenetic approach to recover integration dates of latent HIV sequences within-host

    Article • Proceedings of the National Academy of Sciences, September 2018, Proceedings of the National Academy of Sciences

    Dr Mark A Brockman

  22. HLA-C downregulation by HIV-1 adapts to host HLA genotype

    Article • PLoS Pathogens, September 2018, PLOS

    Dr Mark A Brockman

  23. Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection

    Article • Journal of Virology, July 2018, ASM Journals

    Dr Mark A Brockman

  24. Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products

    Article • Viruses, June 2018, MDPI AG

    Dr Mark A Brockman

  25. Novel HLA class I associations with HIV-1 control in a unique genetically admixed population

    Article • Scientific Reports, April 2018, Springer Science + Business Media

    Dr Mark A Brockman

  26. Inhibition of NF-κB-dependent HIV-1 replication by the marine natural product bengamide A

    Article • Antiviral Research, April 2018, Elsevier

    Dr Mark A Brockman

  27. High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia

    Article • Viruses, February 2018, MDPI AG

    Dr Mark A Brockman

  28. The Croton megalobotrys Müll Arg. traditional medicine in HIV/AIDS management: Documentation of patient use, in vitro activation of latent HIV-1 provirus, and isolation of active phorbol esters

    Article • Journal of Ethnopharmacology, January 2018, Elsevier

    Dr Mark A Brockman

  29. Weaker HLA Footprints on HIV in the Unique and Highly Genetically Admixed Host Population of Mexico

    Article • Journal of Virology, November 2017, ASM Journals

    Dr Mark A Brockman

  30. Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals

    Article • Journal of Virology, October 2017, ASM Journals

    Dr Takamasa Ueno, Dr Mark A Brockman

  31. Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-Driven Replication Capacity

    Article • Journal of Virology, June 2017, ASM Journals

    Dr Mark A Brockman

  32. Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity

    Article • Journal of Virology, June 2017, ASM Journals

    Dr Andres Finzi, Dr Mark A Brockman

  33. Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression

    Article • Journal of Virology, April 2017, ASM Journals

    Dr Mark A Brockman

  34. In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach

    Article • Journal of Virological Methods, February 2017, Elsevier

    Dr Mark A Brockman

  35. Sesterterpenoids Isolated from the Sponge Phorbas sp. Activate Latent HIV-1 Provirus Expression

    Article • The Journal of Organic Chemistry, November 2016, American Chemical Society (ACS)

    Dr Mark A Brockman

  36. Croton megalobotrys Müll Arg. and Vitex doniana (Sweet): Traditional medicinal plants in a three-step treatment regimen that inhibit in vitro replication of HIV-1

    Article • Journal of Ethnopharmacology, September 2016, Elsevier

    Dr Mark A Brockman

  37. Novel Acylguanidine-Based Inhibitor of HIV-1

    Article • Journal of Virology, August 2016, ASM Journals

    Dr Mark A Brockman

  38. Impact of pre-adapted HIV transmission

    Article • Nature Medicine, May 2016, Springer Science + Business Media

    Dr Mark A Brockman

  39. HIV-1 Vpu Mediates HLA-C Downregulation

    Article • Cell Host & Microbe, May 2016, Elsevier

    Dr Mark A Brockman

  40. Diagnostic Accuracy of the HemoCue Hb 301, STAT-Site MHgb and URIT-12 Point-of-Care Hemoglobin Meters in a Central Laboratory and a Community Based Clinic in Durban, South Africa

    Article • PLoS ONE, April 2016, PLOS

    Dr Mark A Brockman

  41. Relative Resistance of HLA-B to Downregulation by Naturally Occurring HIV-1 Nef Sequences

    Article • mBio, January 2016, ASM Journals

    Dr Takamasa Ueno, Dr Mark A Brockman

  42. Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity

    Article • Journal of Virology, December 2015, ASM Journals

    Dr Andres Finzi, Dr Mark A Brockman

  43. A robust and scalable TCR-based reporter cell assay to measure HIV-1 Nef-mediated T cell immune evasion

    Article • Journal of Immunological Methods, November 2015, Elsevier

    Dr Takamasa Ueno, Dr Mark A Brockman

  44. Unciaphenol, an Oxygenated Analogue of the Bergman Cyclization Product of Uncialamycin Exhibits Anti-HIV Activity

    Article • Organic Letters, October 2015, American Chemical Society (ACS)

    Dr Mark A Brockman

  45. Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs

    Article • Frontiers in Immunology, October 2015, Frontiers

    Dr Mark A Brockman

  46. Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function

    Article • Journal of Virology, September 2015, ASM Journals

    Dr Mark A Brockman

  47. Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry Receptors

    Article • Journal of Virology, July 2015, ASM Journals

    Dr Takamasa Ueno, Dr Mark A Brockman

  48. Implementation of couples’ voluntary HIV counseling and testing services in Durban, South Africa

    Article • BMC Public Health, July 2015, Springer Science + Business Media

    Dr Mark A Brockman

  49. Dynamic range of Nef-mediated evasion of HLA class II-restricted immune responses in early HIV-1 infection

    Article • Biochemical and Biophysical Research Communications, July 2015, Elsevier

    Dr Takamasa Ueno, Dr Mark A Brockman

  50. Knowledge of HIV Serodiscordance, Transmission, and Prevention among Couples in Durban, South Africa

    Article • PLoS ONE, April 2015, PLOS

    Dr Mark A Brockman

  51. Screening of the Pan-African Natural Product Library Identifies Ixoratannin A-2 and Boldine as Novel HIV-1 Inhibitors

    Article • PLoS ONE, April 2015, PLOS

    Dr Mark A Brockman

  52. Immune Screening Identifies Novel T Cell Targets Encoded by Antisense Reading Frames of HIV-1

    Article • Journal of Virology, January 2015, ASM Journals

    Dr Mark A Brockman

  53. Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence

    Article • Proceedings of the National Academy of Sciences, December 2014, Proceedings of the National Academy of Sciences

    Dr Mark A Brockman

  54. Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: Association with disease progression and influence of immune pressure

    Article • Virology, November 2014, Elsevier

    Dr Mark A Brockman

  55. Impaired Nef Function Is Associated with Early Control of HIV-1 Viremia

    Article • Journal of Virology, June 2014, ASM Journals

    Dr Mark A Brockman

  56. Genotypic and Functional Impact of HIV-1 Adaptation to Its Host Population during the North American Epidemic

    Article • PLoS Genetics, April 2014, PLOS

    Dr Mark A Brockman

  57. Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes

    Article • Retrovirology, September 2013, Springer Science + Business Media

    Dr Mark A Brockman

  58. Naturally-arising amino acid polymorphisms of HIV-1 Nef that differentially modulate downregulation of HLA-A and HLA-B molecules

    Article • Retrovirology, September 2013, Springer Science + Business Media

    Dr Mark A Brockman, Dr Takamasa Ueno

  59. No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial

    Article • PLoS ONE, August 2013, PLOS

    Dr Mark A Brockman

  60. Dynamic range of Nef functions in chronic HIV-1 infection

    Article • Virology, May 2013, Elsevier

    Dr Mark A Brockman, Dr Takamasa Ueno

  61. HIV-1 Nef and T-cell activation: a history of contradictions

    Article • Future Virology, April 2013, Future Medicine

    Dr Mark A Brockman

  62. Attenuation of multiple Nef functions in HIV-1 elite controllers

    Article • Retrovirology, January 2013, Springer Science + Business Media

    Dr Mark A Brockman, Dr Takamasa Ueno

  63. Significant Reductions in Gag-Protease-Mediated HIV-1 Replication Capacity during the Course of the Epidemic in Japan

    Article • Journal of Virology, November 2012, ASM Journals

    Dr Mark A Brockman

  64. HERV-K–specific T cells eliminate diverse HIV-1/2 and SIV primary isolates

    Article • Journal of Clinical Investigation, November 2012, American Society for Clinical Investigation

    Dr Mark A Brockman

  65. Correlates of Protective Cellular Immunity Revealed by Analysis of Population-Level Immune Escape Pathways in HIV-1

    Article • Journal of Virology, October 2012, ASM Journals

    Dr Mark A Brockman

  66. Brockman, M.A., et al., Human Leukocyte Antigen (HLA) Class I Down-Regulation by Human Immunodeficiency Virus Type 1 Negative Factor (HIV-1 Nef): What Might We Learn From Natural Sequence Variants? Viruses 2012, 4, 1711-1730

    Article • Viruses, October 2012, MDPI AG

    Dr Mark A Brockman, Dr Takamasa Ueno

  67. Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cure

    Article • Current Opinion in Virology, October 2012, Elsevier

    Dr Mark A Brockman

  68. Intersubtype Differences in the Effect of a Rare p24 Gag Mutation on HIV-1 Replicative Fitness

    Article • Journal of Virology, September 2012, ASM Journals

    Dr Mark A Brockman

  69. Human Leukocyte Antigen (HLA) Class I Down-Regulation by Human Immunodeficiency Virus Type 1 Negative Factor (HIV-1 Nef): What Might We Learn From Natural Sequence Variants?

    Article • Viruses, September 2012, MDPI AG

    Dr Mark A Brockman, Dr Takamasa Ueno

  70. Limited evidence for alterations in Gag-mediated HIV replication capacity over the course of the North American epidemic (1979-present)

    Article • Retrovirology, September 2012, Springer Science + Business Media

    Dr Mark A Brockman

  71. T cell receptor clonotypes modulate the protective effect of human leukocyte antigen class I alleles in HIV-1 infection

    Article • Retrovirology, September 2012, Springer Science + Business Media

    Dr Mark A Brockman

  72. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection

    Article • Nature Immunology, June 2012, Springer Science + Business Media

    Dr Mark A Brockman

  73. Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity

    Article • Journal of Virology, April 2012, ASM Journals

    Dr Mark A Brockman

  74. Impact of HLA-B*81-Associated Mutations in HIV-1 Gag on Viral Replication Capacity

    Article • Journal of Virology, January 2012, ASM Journals

    Dr Mark A Brockman

  75. Lack of Association between HLA Class II Alleles and In Vitro Replication Capacities of Recombinant Viruses Encoding HIV-1 Subtype C Gag-Protease from Chronically Infected Individuals

    Article • Journal of Virology, November 2011, ASM Journals

    Dr Mark A Brockman

  76. Corrigendum

    Article • Future Virology, November 2011, Future Medicine

    Dr Mark A Brockman

  77. Impairment of viral replication capacity by nef alleles from HIV elite controllers

    Article • Retrovirology, October 2011, Springer Science + Business Media

    Dr Mark A Brockman, Dr Takamasa Ueno

  78. Immune-mediated attenuation of HIV-1

    Article • Future Virology, August 2011, Future Medicine

    Dr Mark A Brockman

  79. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade

    Article • Blood, July 2011, American Society of Hematology

    Dr Mark A Brockman

  80. Progression to AIDS in South Africa Is Associated with both Reverting and Compensatory Viral Mutations

    Article • PLoS ONE, April 2011, PLOS

    Dr Mark A Brockman, Dr Christopher John Seebregts

  81. HIV infection increases HCV-induced hepatocyte apoptosis

    Article • Journal of Hepatology, April 2011, Elsevier

    Dr Mark A Brockman, Dr Wenyu Lin

  82. Influence of Gag-Protease-Mediated Replication Capacity on Disease Progression in Individuals Recently Infected with HIV-1 Subtype C

    Article • Journal of Virology, February 2011, ASM Journals

    Dr Mark A Brockman

  83. Reduced Replication Capacity of NL4-3 Recombinant Viruses Encoding Reverse Transcriptase–Integrase Sequences From HIV-1 Elite Controllers

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, February 2011, Wolters Kluwer Health

    Dr Mark A Brockman

  84. HIV and HCV Cooperatively Promote Hepatic Fibrogenesis via Induction of Reactive Oxygen Species and NFκB

    Article • Journal of Biological Chemistry, November 2010, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Mark A Brockman, Dr Wenyu Lin

  85. In Vitro Selection of Clinically Relevant Bevirimat Resistance Mutations Revealed by "Deep" Sequencing of Serially Passaged, Quasispecies-Containing Recombinant HIV-1

    Article • Journal of Clinical Microbiology, November 2010, ASM Journals

    Dr Mark A Brockman

  86. Early Selection in Gag by Protective HLA Alleles Contributes to Reduced HIV-1 Replication Capacity That May Be Largely Compensated for in Chronic Infection

    Article • Journal of Virology, September 2010, ASM Journals

    Dr Mark A Brockman

  87. Gag-Protease-Mediated Replication Capacity in HIV-1 Subtype C Chronic Infection: Associations with HLA Type and Clinical Parameters

    Article • Journal of Virology, August 2010, ASM Journals

    Dr Mark A Brockman

  88. Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers

    Article • Journal of Virology, May 2010, ASM Journals

    Dr Mark A Brockman

  89. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR)

    Article • Psychiatry Research, April 2010, Elsevier

    Dr Mark A Brockman

  90. Viral adaptation to immune selection pressure by HLA class I–restricted CTL responses targeting epitopes in HIV frameshift sequences

    Article • The Journal of Experimental Medicine, January 2010, Rockefeller University Press

    Dr Mark A Brockman

  91. HLA-Associated Viral Mutations Are Common in Human Immunodeficiency Virus Type 1 Elite Controllers

    Article • Journal of Virology, December 2009, ASM Journals

    Dr Mark A Brockman

  92. P09-19 LB. CTL escape mutations in gag epitopes restricted by protective HLA class I alleles cause substantial reductions in viral replication capacity

    Article • Retrovirology, October 2009, Springer Science + Business Media

    Dr Mark A Brockman

  93. P09-11. Reduced replication capacity of NL4-3 chimeric viruses encoding RT-Integrase sequences from HIV-1 elite controllers

    Article • Retrovirology, October 2009, Springer Science + Business Media

    Dr Mark A Brockman

  94. P16-41. Evidence for in vivo immune selection pressure exerted by HLA class I restricted CTL responses to anti-sense encoded HIV sequences

    Article • Retrovirology, October 2009, Springer Science + Business Media

    Dr Mark A Brockman

  95. P09-10. Impact of CTL escape mutations in HIV-1 Nef on viral replication

    Article • Retrovirology, October 2009, Springer Science + Business Media

    Dr Mark A Brockman

  96. P09-09. Impact of immune-driven sequence variation in HIV-1 subtype C Gag-Protease on viral fitness and disease progression

    Article • Retrovirology, October 2009, Springer Science + Business Media

    Dr Mark A Brockman

  97. P16-55 LB. The role of CD4+ CD25+ regulatory T cells in the control of IL-10 mediated T cell impairment in chronic HIV Infection

    Article • Retrovirology, October 2009, Springer Science + Business Media

    Dr Mark A Brockman

  98. HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins

    Article • PLoS ONE, August 2009, PLOS

    Dr Mark A Brockman, Dr Nicole Frahm

  99. Maternal Transmission of Human Immunodeficiency Virus Escape Mutations Subverts HLA-B57 Immunodominance but Facilitates Viral Control in the Haploidentical Infant

    Article • Journal of Virology, June 2009, ASM Journals

    Dr Mark A Brockman

  100. HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphocyte Recognition

    Article • Journal of Virology, June 2009, ASM Journals

    Dr Mark A Brockman

  101. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells

    Article • Blood, April 2009, American Society of Hematology

    Dr Mark A Brockman

  102. Differential Neutralization of Human Immunodeficiency Virus (HIV) Replication in Autologous CD4 T Cells by HIV-Specific Cytotoxic T Lymphocytes

    Article • Journal of Virology, January 2009, ASM Journals

    Dr Mark A Brockman

  103. HLA-Associated Viral Mutations Are Common in Human Immunodeficiency Virus Type 1 Elite Controllers

    Article • Journal of Virology, January 2009, ASM Journals

    Dr Mark A Brockman

  104. HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition

    Article • Journal of Virology, December 2008, ASM Journals

    Dr Mark A Brockman

  105. Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection

    Article • Vaccine, December 2008, Elsevier

    Dr Mark A Brockman

  106. Type 2 Bias of T Cells Expanded from the Blood of Melanoma Patients Switched to Type 1 by IL-12p70 mRNA-Transfected Dendritic Cells

    Article • Cancer Research, November 2008, American Association for Cancer Research (AACR)

    Dr Mark A Brockman

  107. HLA-Associated Alterations in Replication Capacity of Chimeric NL4-3 Viruses Carrying gag-protease from Elite Controllers of Human Immunodeficiency Virus Type 1

    Article • Journal of Virology, October 2008, ASM Journals

    Dr Mark A Brockman

  108. Genetic Characterization of Human Immunodeficiency Virus Type 1 in Elite Controllers: Lack of Gross Genetic Defects or Common Amino Acid Changes

    Article • Journal of Virology, June 2008, ASM Journals

    Dr Mark A Brockman

  109. Quantitative Effect of Suboptimal Codon Usage on Translational Efficiency of mRNA Encoding HIV-1 gag in Intact T Cells

    Article • PLoS ONE, June 2008, PLOS

    Dr Mark A Brockman

  110. Structural and Functional Constraints Limit Options for Cytotoxic T-Lymphocyte Escape in the Immunodominant HLA-B27-Restricted Epitope in Human Immunodeficiency Virus Type 1 Capsid

    Article • Journal of Virology, April 2008, ASM Journals

    Dr Mark A Brockman

  111. Rapid ex vivo isolation and long-term culture of human Th17 cells

    Article • Journal of Immunological Methods, April 2008, Elsevier

    Dr Mark A Brockman

  112. Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands

    Article • AIDS, March 2008, Wolters Kluwer Health

    Dr Mark A Brockman

  113. HIV Increases HCV Replication in a TGF-β1–Dependent Manner

    Article • Gastroenterology, March 2008, Elsevier

    Dr Mark A Brockman, Dr Wenyu Lin

  114. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction

    Article • Nature Immunology, September 2007, Springer Science + Business Media

    Dr Mark A Brockman, Professor John M Coffin

  115. Escape from the Dominant HLA-B27-Restricted Cytotoxic T-Lymphocyte Response in Gag Is Associated with a Dramatic Reduction in Human Immunodeficiency Virus Type 1 Replication

    Article • Journal of Virology, September 2007, ASM Journals

    Dr Mark A Brockman

  116. Escape and Compensation from Early HLA-B57-Mediated Cytotoxic T-Lymphocyte Pressure on Human Immunodeficiency Virus Type 1 Gag Alter Capsid Interactions with Cyclophilin A

    Article • Journal of Virology, August 2007, ASM Journals

    Dr Mark A Brockman

  117. Selective Depletion of High-Avidity Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+ T Cells after Early HIV-1 Infection

    Article • Journal of Virology, February 2007, ASM Journals

    Dr Mark A Brockman

  118. Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector

    Article • Virology, January 2007, Elsevier

    Dr Mark A Brockman

  119. Optimal Long-Term Humoral Responses to Replication-Defective Herpes Simplex Virus Require CD21/CD35 Complement Receptor Expression on Stromal Cells

    Article • Journal of Virology, July 2006, ASM Journals

    Dr Mark A Brockman

  120. Use of a novel GFP reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry

    Article • Journal of Virological Methods, February 2006, Elsevier

    Dr Mark A Brockman

  121. Myeloid C3 Determines Induction of Humoral Responses to Peripheral Herpes Simplex Virus Infection

    Article • The Journal of Immunology, November 2003, The American Association of Immunologists

    Dr Mark A Brockman

  122. Macrophage-Derived Complement Component C4 Can Restore Humoral Immunity in C4-Deficient Mice

    Article • The Journal of Immunology, November 2002, The American Association of Immunologists

    Dr Mark A Brockman

  123. Herpes Simplex Virus Vectors Elicit Durable Immune Responses in the Presence of Preexisting Host Immunity

    Article • Journal of Virology, April 2002, ASM Journals

    Dr Mark A Brockman

  124. Cutting Edge: Myeloid Complement C3 Enhances the Humoral Response To Peripheral Viral Infection

    Article • The Journal of Immunology, September 2001, The American Association of Immunologists

    Dr Mark A Brockman

  125. Construction, Phenotypic Analysis, and Immunogenicity of a UL5/UL29 Double Deletion Mutant of Herpes Simplex Virus 2

    Article • Journal of Virology, September 2000, ASM Journals

    Dr Mark A Brockman

  126. Local synthesis of C3 in lymphoid tissues is sufficient to restore humoral responses to peripheral herpes simplex virus (HSV-1) infection in C3-deficient mice

    Article • Immunopharmacology, August 2000, Elsevier

    Dr Mark A Brockman

  127. Humoral response to herpes simplex virus is complement-dependent

    Article • Proceedings of the National Academy of Sciences, October 1999, Proceedings of the National Academy of Sciences

    Dr Mark A Brockman

  128. Research in Undergraduate Instruction: A Biotech Lab Project for Recombinant DNA Protein Expression in Bacteria

    Article • Journal of Chemical Education, June 1996, American Chemical Society (ACS)

    Dr Mark A Brockman